MA45620A - Oligonucléotides antisens pour la modulation de l'expression de htra1 - Google Patents

Oligonucléotides antisens pour la modulation de l'expression de htra1

Info

Publication number
MA45620A
MA45620A MA045620A MA45620A MA45620A MA 45620 A MA45620 A MA 45620A MA 045620 A MA045620 A MA 045620A MA 45620 A MA45620 A MA 45620A MA 45620 A MA45620 A MA 45620A
Authority
MA
Morocco
Prior art keywords
modulation
oligonucleotides
antisens
htra1
expression
Prior art date
Application number
MA045620A
Other languages
English (en)
Inventor
Peter Hagedorn
Heidi Hudlebusch
Roberto Iacone
Susanne Kammler
Søren Ottosen
Lykke Pedersen
Sindri Traustason
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA45620A publication Critical patent/MA45620A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La présente invention concerne des oligonucléotides antisens (oligomères) complémentaires de htra1, conduisant à une modulation de l'expression de htra1. La modulation de l'expression de htra est bénéfique pour une gamme de troubles médicaux, tels que la dégénérescence maculaire, par exemple. Dégénérescence maculaire liée à l'âge.
MA045620A 2016-07-01 2017-06-28 Oligonucléotides antisens pour la modulation de l'expression de htra1 MA45620A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177508 2016-07-01
EP17170129 2017-05-09

Publications (1)

Publication Number Publication Date
MA45620A true MA45620A (fr) 2019-05-08

Family

ID=59295175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045620A MA45620A (fr) 2016-07-01 2017-06-28 Oligonucléotides antisens pour la modulation de l'expression de htra1

Country Status (21)

Country Link
US (2) US10519450B2 (fr)
EP (1) EP3478839A1 (fr)
JP (3) JP7060525B2 (fr)
KR (1) KR20190025970A (fr)
CN (2) CN118325897A (fr)
AU (1) AU2017289204A1 (fr)
BR (1) BR112018077321A2 (fr)
CA (1) CA3026855A1 (fr)
CL (1) CL2018003698A1 (fr)
CO (1) CO2018013240A2 (fr)
CR (1) CR20180606A (fr)
IL (1) IL263489A (fr)
MA (1) MA45620A (fr)
MX (1) MX2018015722A (fr)
PE (1) PE20190381A1 (fr)
PH (1) PH12018502707A1 (fr)
RU (1) RU2019101298A (fr)
SG (2) SG11201811554SA (fr)
TW (1) TW201803990A (fr)
WO (1) WO2018002105A1 (fr)
ZA (1) ZA201808291B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
CN109476637B (zh) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
CR20180606A (es) * 2016-07-01 2019-02-14 Hoffmann La Roche Oligonucleótidos antisentido para modular la expresión de htra1
KR20200104302A (ko) 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 신규 티오포스포르아미다이트
US20200339982A1 (en) 2017-12-22 2020-10-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
KR20200104347A (ko) 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
WO2020007772A1 (fr) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant gbp-1
WO2020109344A1 (fr) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Dispositif d'administration oculaire pour oligonucléotides antisens
WO2020109343A1 (fr) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Polythérapie pour le traitement de la dégénérescence maculaire

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
WO2000008134A2 (fr) 1998-08-03 2000-02-17 Novartis Ag SERINE PROTEASE DE HtrA HUMAINE
KR100573231B1 (ko) 1999-02-12 2006-04-24 상꾜 가부시키가이샤 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
EP2752488B1 (fr) 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Conception antisens
WO2006127913A2 (fr) 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Compositions et utilisations dans la lmw-ptpase
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
CA2640171C (fr) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en position 6
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
MX2009000909A (es) 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
US20100166743A1 (en) 2006-10-06 2010-07-01 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2170917B1 (fr) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
TW200911290A (en) 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
US20100303832A1 (en) 2007-11-01 2010-12-02 Hageman Gregory S Genes and polymorphisms associated with amd
WO2009067647A1 (fr) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
WO2011017521A2 (fr) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques cyclohexoses bicycliques
EP2580228B1 (fr) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. 2' amino- et 2' thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
FR2965278B1 (fr) 2010-09-23 2014-10-10 Univ Caen Basse Normandie Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
CA2863253A1 (fr) 2011-09-07 2013-03-14 Marina Biotech, Inc. Synthese et utilisations de composes acides nucleiques comportant des monomeres restreints de point de vue conformationnel
EP2850092B1 (fr) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Analogues tricycliques d'acide nucléique
US20150141320A1 (en) 2012-05-16 2015-05-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
JP6452614B2 (ja) 2012-11-15 2019-01-16 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドコンジュゲート
NZ741780A (en) 2015-10-30 2019-11-29 Genentech Inc Anti-htra1 antibodies and methods of use thereof
CR20180606A (es) * 2016-07-01 2019-02-14 Hoffmann La Roche Oligonucleótidos antisentido para modular la expresión de htra1
US20190284621A1 (en) 2016-11-11 2019-09-19 Roche Innovation Center Copenhagen A/S Therapeutic oligonucleotides capture and detection
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression

Also Published As

Publication number Publication date
US10519450B2 (en) 2019-12-31
TW201803990A (zh) 2018-02-01
JP2024029178A (ja) 2024-03-05
ZA201808291B (en) 2019-10-30
CA3026855A1 (fr) 2018-01-04
CR20180606A (es) 2019-02-14
CO2018013240A2 (es) 2018-12-14
JP7060525B2 (ja) 2022-04-26
JP7416852B2 (ja) 2024-01-17
CN118325897A (zh) 2024-07-12
US20180002701A1 (en) 2018-01-04
CL2018003698A1 (es) 2019-04-05
KR20190025970A (ko) 2019-03-12
CN109415732B (zh) 2024-01-02
MX2018015722A (es) 2019-05-27
CN109415732A (zh) 2019-03-01
PH12018502707A1 (en) 2019-11-11
EP3478839A1 (fr) 2019-05-08
PE20190381A1 (es) 2019-03-08
SG11201811554SA (en) 2019-01-30
SG10202005885VA (en) 2020-07-29
JP2022106785A (ja) 2022-07-20
RU2019101298A (ru) 2020-08-03
RU2019101298A3 (fr) 2021-01-26
AU2017289204A1 (en) 2019-01-17
WO2018002105A1 (fr) 2018-01-04
IL263489A (en) 2019-01-31
JP2019522987A (ja) 2019-08-22
BR112018077321A2 (pt) 2019-04-24
US20200399641A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MA45620A (fr) Oligonucléotides antisens pour la modulation de l'expression de htra1
MA51530B1 (fr) Composés cycliques fondus
ECSP20075270A (es) Compuestos
MX2021003478A (es) Compuestos utiles como inhibidores de cinasa.
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
GEAP202115183A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EA201690372A1 (ru) Азапиридоновые соединения и их применение
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA40895B1 (fr) Synthèse de copanlisib et son sel de dichlorhydrate
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MX388696B (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
BR112021017661A2 (pt) Uso de compostos 8,9-di-hidrocanabidiol
PH12019502636A1 (en) Antisense oligonucleotides for modulating htra1 expression
MX386618B (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
MX388697B (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
FR3078704B1 (fr) Derives d'isohexide et leurs utilisations
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
MX2022013814A (es) Tratamiento de infecciones virales.
FR3060003B1 (fr) Compose derive des 4,5-diaminopyrazoles a cycle fusionne, composition comprenant au moins un tel compose, procede de mise en oeuvre et utilisation
ZA202507396B (en) Fused ring compounds
MA42296B1 (fr) Composés antibactériens
MA47497B1 (fr) Di-nucléotides cycliques utilisés pour le traitement du cancer
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
MA42871B1 (fr) Composés utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk)